From Wikipedia, the free encyclopedia
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetHLA-DR beta
Clinical data
ATC code
  • none
CAS Number
  • none
 ☒NcheckY (what is this?)  (verify)

Apolizumab is a humanized monoclonal antibody intended for use in hematologic cancers.[1][2] Development was abandoned in 2005, because of toxic effects and lack of efficacy in humans. The observed dose limiting toxic effects were aseptic meningitis and hemolytic uremia.[3]


  1. ^ Bayes M, Rabasseda X, Prous JR (November 2003). "Gateways to clinical trials". Methods and Findings in Experimental and Clinical Pharmacology. 25 (9): 747–771. PMID 14685303.
  2. ^ Rech J, Repp R, Rech D, Stockmeyer B, Dechant M, Niedobitek G, et al. (October 2006). "A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study". Leukemia & Lymphoma. 47 (10): 2147–2154. doi:10.1080/10428190600757944. PMID 17071489. S2CID 24080973.
  3. ^ Lin TS, Stock W, Xu H, Phelps MA, Lucas MS, Guster SK, et al. (December 2009). "A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia". Leukemia & Lymphoma. 50 (12): 1958–1963. doi:10.3109/10428190903186486. PMC 8166408. PMID 19860603. S2CID 22328921.